Today: 22 January 2026
Subscribe
Browse Category

SGX:D05 News 20 January 2026 - 22 January 2026

DBS share price today: DBS stock steadies near S$58 as Singapore bank earnings loom

DBS share price today: DBS stock steadies near S$58 as Singapore bank earnings loom

Singapore, Jan 22, 2026, 14:49 SGT — Regular session Shares of DBS Group Holdings Ltd ticked up 0.1% to S$58.08 by early afternoon in Singapore, following a 0.2% drop Wednesday. Trading volume hit roughly 2.1 million shares, according to MarketScreener data. (MarketScreener) Singapore’s banks continue to dominate the local index, making this move significant as traders seek an edge ahead…
22 January 2026
····
OCBC stock price ticks up as Bank of Singapore names new CFO and investors eye Feb 25 results

OCBC stock price ticks up as Bank of Singapore names new CFO and investors eye Feb 25 results

Singapore, Jan 20, 2026, 15:12 SGT — Regular session Oversea-Chinese Banking Corp’s shares nudged higher Tuesday, bucking the downward trend among Singapore’s major banks. OCBC (O39.SGX) gained roughly 0.1%, trading at S$20.33 in the afternoon, up from Monday’s close of S$20.31. (Google) The real challenge won’t be today’s price action, but the update due next month. OCBC told the Singapore…
20 January 2026
·······
DBS share price dips after CGS downgrade, with Feb. 9 results the next test

DBS share price dips after CGS downgrade, with Feb. 9 results the next test

Singapore, January 20, 2026, 14:50 SGT — Regular session Shares of DBS Group Holdings Ltd fell 0.8% to S$58.26 by 2:50 p.m. in Singapore, pulling back from a session high just shy of its 52-week peak following a broker downgrade. The stock traded between S$58.13 and S$58.63 and still hovers close to its 52-week high of S$59.25. (Google) Timing is…
20 January 2026
·····

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop